Medicines Australia Advisory Council
The Medicines Australia Advisory Council provides advice to the Board on trends and issues impacting the pharmaceutical industry in the medium to long term to support the Board’s role in shaping strategy.
The Advisory Council offers a strategic and diverse perspective of the environment with a view to positively shaping the future of the industry. This includes:
> Consideration of domestic and international factors that will impact on the industry and its members over the next 5-10 years such as demographic, political, social, economic, technological, scientific, regulatory and legislative.
>Identifying relevant, prioritised and strategic issues – risks, opportunities and trends – that may inform Australia’s industry, health and medicines policy and may impact Medicines Australia and its members.
>Identifying potential options that will enable Medicines Australia to positively shape the operating environment.
The Council meets several times throughout the year and is chaired by a Director of the Medicines Australia Board. It is guided in its work by direction from the Board.
Established in 2017, the Council comprises 8-10 individuals appointed on a skills-based matrix and includes one representative currently employed by a member organisation.
Current Advisory Council members
Mr Patrick Desbiens, Senior Vice-President & General Manager, Australia & New Zealand GSK (Chair)
Mr Greg Allen, FCHSM, CHE, Finance Manager, Epworth Freemasons Hospital
Dr Leigh Farrell, FAICD, Executive Advisor to Certara C-Suite
Ms Renae Beardmore BPharm, MBA, MPS, GAICD, Managing Director EvoHealth
Mr Richard Vines, Founder and Chair of Rare Cancers Australia
Ms Tamara Dawson B.Com, B.A, Founder of the Melanoma & Skin Cancer Advocacy Network (MSCAN)
Mr Sergio Duchini FTA CTA GAICD, Non-Executive Director Enlitic
Ms Anne-Marie Perret GAICD, Governance Adviser & Board Director
Dr Kathryn Evans Dip. Pharm., M.B.A., Doctor of Bus. Admin., GAICD, Managing Director of BioMarin Pharmaceutical Australia